Suppr超能文献

相似文献

1
Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.
World J Gastroenterol. 2009 Sep 28;15(36):4529-37. doi: 10.3748/wjg.15.4529.
6
Tetrandrine ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
J Huazhong Univ Sci Technolog Med Sci. 2004;24(4):385-8, 395. doi: 10.1007/BF02861874.
9
Current concepts on the role of nitric oxide in portal hypertension.
World J Gastroenterol. 2013 Mar 21;19(11):1707-17. doi: 10.3748/wjg.v19.i11.1707.

引用本文的文献

1
Emerging Therapeutic Targets for Portal Hypertension.
Curr Hepatol Rep. 2023;22(1):51-66. doi: 10.1007/s11901-023-00598-4. Epub 2023 Feb 11.
3
Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.
Int J Mol Sci. 2021 Jul 29;22(15):8139. doi: 10.3390/ijms22158139.
4
Taurine mitigates bile duct obstruction-associated cholemic nephropathy: effect on oxidative stress and mitochondrial parameters.
Clin Exp Hepatol. 2021 Mar;7(1):30-40. doi: 10.5114/ceh.2021.104675. Epub 2021 Mar 25.
5
Taurine mitigates cirrhosis-associated heart injury through mitochondrial-dependent and antioxidative mechanisms.
Clin Exp Hepatol. 2020 Sep;6(3):207-219. doi: 10.5114/ceh.2020.99513. Epub 2020 Sep 30.
8
Advances in therapeutic options for portal hypertension.
Therap Adv Gastroenterol. 2018 Nov 25;11:1756284818811294. doi: 10.1177/1756284818811294. eCollection 2018.
9
Novel treatment options for portal hypertension.
Gastroenterol Rep (Oxf). 2017 May;5(2):90-103. doi: 10.1093/gastro/gox011. Epub 2017 Apr 18.
10
Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension?
Biomed Res Int. 2014;2014:797898. doi: 10.1155/2014/797898. Epub 2014 Apr 9.

本文引用的文献

1
Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice.
Hum Exp Toxicol. 2007 Jun;26(6):509-18. doi: 10.1177/0960327107072392.
2
Effects of taurine in cellular responses to oxidative stress in young and middle-aged rat liver.
Ann N Y Acad Sci. 2007 Apr;1100:553-61. doi: 10.1196/annals.1395.061.
3
The future treatment of portal hypertension.
Best Pract Res Clin Gastroenterol. 2007;21(1):191-202. doi: 10.1016/j.bpg.2006.07.006.
4
Substantia nigra osmoregulation: taurine and ATP involvement.
Am J Physiol Cell Physiol. 2007 May;292(5):C1934-41. doi: 10.1152/ajpcell.00593.2006. Epub 2007 Jan 10.
5
Hepatic fibrosis, stellate cells, and portal hypertension.
Clin Liver Dis. 2006 Aug;10(3):459-79, vii-viii. doi: 10.1016/j.cld.2006.08.017.
6
Molecular and structural basis of portal hypertension.
Clin Liver Dis. 2006 Aug;10(3):445-57, vii. doi: 10.1016/j.cld.2006.08.011.
7
Taurine, taurine analogues, and taurine functions: overview.
Adv Exp Med Biol. 2006;583:443-8. doi: 10.1007/978-0-387-33504-9_51.
9
10
Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model.
World J Gastroenterol. 2005 Nov 7;11(41):6483-8. doi: 10.3748/wjg.v11.i41.6483.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验